Diaceutics PLC

We are one week away from our next webinar - The Medical Laboratory Scientist: The First Step of Blood Cancer Personalized Medicine. Don’t miss out and sign up now: https://lnkd.in/eirkcuyM In this session, our speaker Dr. Rachel Mariani, Hematopathology Section Director and Medical Director, Phoenix Children's Hospital, will highlight the importance of fundamental laboratory methods in diagnosis, prognosis, treatment of blood cancers in pediatrics and adult patients. Join us on 12th September, 10am EDT for an engaging session! #BloodCancerAwarenessMonth

Just one day to go until our webinar, “Driving Commercial Success for Precision Medicine: Understand the Market to Maximize Patient Identification & Therapy Adoption.” Join us on tomorrow, September 5, 2024, from 1-2pm EDT, where precision medicine expert Kevin Entwistle will discuss how to leverage Diaceutics’ 6A™ Commercial Framework to navigate market challenges, utilize real-world data, and enhance patient identification to drive therapy adoption and improve outcomes. Gain exclusive insights into market trends and the patient journey, discover how real-world data and deep market insights can position your therapy for commercial success, and understand the current reimbursement landscape and its impact on adoption, access, and testing behavior. Don’t miss this opportunity to ask Kevin about your challenges! Register here: https://lnkd.in/ep--Jn6f #PrecisionMedicine #Webinar

Are you struggling to achieve commercial success for your targeted therapy?  Join us on Thursday, September 5, 2024, from 1-2pm EDT where Precision medicine expert Kevin Entwistle will discuss how to use Diaceutics’ 6A™ Commercial Framework to navigate market challenges, utilize real-world data, and enhance patient identification to drive therapy adoption and improve outcomes. Gain exclusive insights to drive therapy adoption with a comprehensive understanding of market trends and the patient journey and discover how real-world data and deep market insights can position your therapy for commercial success. Register today: https://lnkd.in/ep--Jn6f #PrecisionMedicine #Webinar

Meet our team attending ESMO! Schedule a meeting with our team at ESMO and discover how Diaceutics’ 6A™ Commercial Framework enables you to navigate market challenges, utilize real-world data, and enhance patient identification to drive therapy adoption and improve outcomes. Learn more about how DXRX Lab Engage enables you to drive biomarker testing adoption and quality through access to Diaceutics’ global lab network, specializing in genomics and precision medicine biomarkers. Schedule a meeting here: https://lnkd.in/eUSxEiqH #ESMO2024 #PrecisionMedicine #Oncology

At Diaceutics we believe in Better Testing, Better Treatment and this September, we are committed to raising awareness this Blood Cancer Awareness Month.   Throughout September, we invite you to join us as we strive to educate and inform through industry expertise!   We will be hosting LabTalks featuring leading experts in their field, along with Blood Cancer related insights exclusive to our DXRX platform.   Stay tuned for more details on our upcoming LabTalks and content releases throughout this month. Find out more - https://lnkd.in/eF_7tDiW

Precision medicine continues to revolutionize healthcare, extending beyond oncology to areas like neurology and immune-mediated inflammatory diseases (IMIDs). At Diaceutics, we are at the forefront of this, helping to navigate the complexities and maximize the impact of precision medicine strategies to our clients. Advances in genetic studies are paving the way for personalized therapies in various fields. For instance, in neurology, precision medicine is making strides in treating diseases like Alzheimer’s and Parkinson’s. Similarly, in IMIDs, a nuanced approach is required to manage conditions like rheumatoid arthritis and lupus. This year, we have explored these areas in more depth, focusing on precision medicine within IMIDs and neurology, and how the field is ever-evolving and expanding, making a robust launch strategy essential. Join us for our upcoming webinar, “Driving Commercial Success for Precision Medicine: Understand the Market to Maximize Patient Identification and Therapy Adoption” on Thursday, 5th September, 1-2pm EDT where precision medicine expert Kevin Entwistle will discuss how to use Diaceutics’ 6A™ Commercial Framework to navigate market challenges, utilize real-world data, and enhance patient identification to drive therapy adoption and improve outcomes. Discover how real-world data and deep market insights can position your therapy for commercial success, and unlock exclusive insights to drive therapy adoption through gaining a comprehensive understanding of market trends and the patient journey. Register here: https://lnkd.in/ep--Jn6f #PrecisionMedicine #Neurology #IMIDs #Oncology #HealthcareInnovation #Diaceutics #Webinar

Miss the latest episode of the Better Testing, Better Treatment podcast? Our guests, Dr. James Solomon and Dr. Ashish Saxena, dive deep into the diverse and rapidly evolving but highly important topic of practical considerations for oncogenic fusion detection and reporting. This episode is packed with insights you don’t want to miss! You can catch up on “Oncogenic Fusion detection and reporting in NSCLC and solid tumors: from clinic to lab” now. https://lnkd.in/eYF_PCrG

The countdown is on! Just one week to go until our webinar: “Driving Commercial Success for Precision Medicine: Understand the Market to Maximize Patient Identification & Therapy Adoption.” Join us on Thursday, September 5, 2024, from 1-2pm EDT where Precision medicine expert Kevin Entwistle will discuss how to use Diaceutics’ 6A™ Commercial Framework to navigate market challenges, utilize real-world data, and enhance patient identification to drive therapy adoption and improve outcomes. Why join? · Exclusive Insights: Drive therapy adoption with a comprehensive understanding of market trends and the patient journey. · Strategic positioning: Discover how real-world data and deep market insights can position your therapy for commercial success. · Market access: Gain insight into the current reimbursement landscape, and how this may affect adoption, access and testing behavior. · Opportunity to ask questions: A unique opportunity to ask Kevin, our experienced PM commercialization expert about your challenges Register today: https://lnkd.in/ep--Jn6f #RareDisease #LabData #PrecisionMedicine

Meet us at ESMO! Our team are looking forward to attending ESMO 2024 Congress in Barcelona, 13-17th September. Schedule a meeting with one of our solution experts using the link below to discover how Diaceutics is uniquely positioned to help you achieve commercialization success for your precision medicine: ·  Global Lab Network: Reach and engage key stakeholders with access to our real-world diagnostic testing data from over 1000 global labs. ·  Real-time engagement solutions: Pinpoint and engage relevant physicians in as little as 24 hours post biomarker testing, educating them on your therapy to drive biomarker testing rates. ·  Real-world-data Insight Solutions: Access the world’s largest diagnostic testing data repository with DXRX – The Diagnostic Network. ·  We have successfully delivered over 160 Market Landscapes since 2017 to 37 world leading pharma and biotech clients across global markets. Schedule a meeting here: https://lnkd.in/eUSxEiqH #ESMO2024 #PrecisionMedicine #Oncology

Despite medical and scientific advances, many patients are still faced with prolonged diagnostic journeys, with multiple referrals and inconclusive test results, often resulting in limited treatment benefits. Today, we are pleased to announce a significant expansion of our lab offering. This strategic enhancement will provide access to a broader range of rare-disease data, revolutionizing the early identification of patients with rare diseases. By leveraging these enhancements, Diaceutics is better positioned to support the timely development and commercialization of targeted therapies, facilitating earlier patient diagnosis and ultimately improving clinical outcomes.  Contact us today to discover how Diaceutics’ unique lab data enhances early patient identification for the development of therapies for rare-diseases: https://lnkd.in/duuUdunz #RareDisease #LabData #PrecisionMedicine